Leukemic phase of Richter transformation: A mimic of acute myeloid leukemia that responded to Ibrutinib monotherapy
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25782
Abstract: Here we report an unusual case of RT without any clinical, laboratory, or radiologic evidence suggestive of transformation other than cytopenia. Without any significant extramedullary involvement, RT presented in a leukemic phase that mimicked acute… read more here.
Keywords: ibrutinib monotherapy; myeloid leukemia; leukemic phase; transformation ... See more keywords
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4765
Abstract: Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy and safety profile of the… read more here.
Keywords: cell lymphoma; relapsed refractory; mantle cell; ibrutinib monotherapy ... See more keywords
Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005425
Abstract: Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy. This led to a phase 1b clinical trial to determine the safety, tolerability, and immunologic… read more here.
Keywords: cell; ibrutinib; ductal adenocarcinoma; ibrutinib monotherapy ... See more keywords
Ibrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Retrospective Single Center Experience from India
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-112348
Abstract: Background: Ibrutinib, a Bruton tyrosine kinase inhibitor, disrupts B-cell antigen receptor signaling pathways that are activated in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Ibrutinib has demonstrated substantial efficacy and received approval by… read more here.
Keywords: mcl; single center; cll; ibrutinib monotherapy ... See more keywords